‘Not Just Growth In AG Xyrem’ Hikma Underlines Following Strong 2023
Lessening Of US Pricing Pressures Also Helps Put Hikma Back On An Even Keel
Executive Summary
Hikma welcomed a strong and profitable 2023, driven by the nourishing effects of its authorized generic Xyrem product, which will fall back this year as the rate of royalties owed to the brand’s innovator climbs. But the company is optimistic it can continue growth in 2024, including through its $1.2bn Injectables division, which rushed in to fill supply gaps last year.